京新药业(002020) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 795,186,882.07, down 15.13% year-on-year, while year-to-date revenue was CNY 2,435,720,765.21, a decrease of 12.87%[9]. - Net profit attributable to shareholders for the reporting period was CNY 147,610,007.99, a decline of 9.55%, with year-to-date net profit at CNY 372,550,098.11, down 23.81%[9]. - Basic earnings per share for the reporting period were CNY 0.2036, a decrease of 14.02%, while year-to-date earnings per share were CNY 0.5231, down 26.27%[9]. - The weighted average return on equity was 3.92%, a decrease of 0.59 percentage points from the previous year[9]. - The net profit for the current period is ¥147,619,334.21, a decrease from ¥163,159,997.11 in the previous period, representing a decline of approximately 9.5%[84]. - The total operating revenue for the current period is ¥445,039,719.65, down from ¥490,226,296.00 in the previous period, indicating a decrease of about 9.2%[88]. - The operating profit for the current period is ¥82,778,889.77, compared to ¥108,945,061.35 in the previous period, reflecting a decline of approximately 24%[88]. - The total profit for the current period is CNY 433,076,648.11, a decrease of 23.8% compared to CNY 568,519,766.85 in the previous period[95]. - The company's total comprehensive income for the current period is CNY 373,806,112.28, down from CNY 477,448,225.01 in the previous period[99]. Cash Flow - The net cash flow from operating activities was CNY 275,271,112.03, an increase of 171.67% compared to the same period last year[9]. - The net cash flow from operating activities for the current period is approximately ¥478.88 million, an increase of 15.1% compared to ¥415.88 million in the previous period[106]. - Cash inflow from investment activities totaled approximately ¥2.34 billion, compared to ¥2.24 billion in the previous period, reflecting a growth of 4.9%[109]. - The net cash flow from investment activities improved significantly to approximately ¥124.64 million, compared to a negative cash flow of ¥311.99 million in the previous period[109]. - The cash flow from financing activities resulted in a net outflow of approximately ¥447.96 million, worsening from a net outflow of ¥149.24 million in the previous period[109]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,463,793,441.55, a decrease of 2.87% compared to the end of the previous year[9]. - The total current assets decreased to ¥3.19 billion from ¥3.49 billion, representing a decline of 8.4% year-over-year[59]. - The company's total liabilities decreased to ¥1.81 billion from ¥1.91 billion, a reduction of 4.5% compared to the previous year[65]. - The total assets of the company as of September 30, 2020, were ¥5.46 billion, down from ¥5.63 billion at the end of 2019, indicating a decrease of 3.0%[68]. - Current liabilities were reported at CNY 1,770,292,227.81, while total liabilities reached CNY 1,914,376,310.28[123]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,109, with the top ten shareholders holding a significant portion of shares[13]. - The largest shareholder, Lü Gang, held 20.55% of the shares, amounting to 148,997,296 shares, with a portion pledged[13]. - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[16]. - The company repurchased a total of 19,364,224 shares, accounting for 2.67% of the total share capital, with a total payment of ¥200.99 million[42]. Investment Activities - The company raised a total of up to ¥500 million through a non-public offering of A-shares, with the number of shares issued not exceeding 54,824,561[39]. - The company reported a net cash outflow from investing activities of ¥124.64 million, a 139.95% decrease compared to the previous year, primarily due to reduced cash outflows from investment activities[38]. - The company recorded investment income of CNY 60,823,121.04, a decrease of 35.9% from CNY 94,894,551.83 in the previous period[95]. Expenses - Total operating costs for the period were CNY 667,952,298.68, down from CNY 795,035,290.10 in the previous period[80]. - Research and development expenses decreased to CNY 44,709,362.74 from CNY 81,247,157.55 year-over-year[80]. - The management expenses increased to CNY 131,010,704.97, up 22.1% from CNY 107,220,538.44 in the previous period[95]. - The tax expenses for the current period are ¥17,525,838.68, compared to ¥12,677,217.45 in the previous period, an increase of about 38.4%[88].